Palisade bio streamlines operations and identifies capital efficiencies to focus all resources on advancement of lead clinical program, lb1148

Carlsbad, calif., sept. 15, 2022 (globe newswire) -- palisade bio, inc. (nasdaq: pali), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, today announced that following an internal strategic review, the management team and board have implemented initiatives to streamline the organization, reduce operating expenses and preserve capital, with the goal of maximizing the advancement of its lead clinical program, lb1148.
PALI Ratings Summary
PALI Quant Ranking